PIH36 Cost-Effectiveness of Palivizumab Use in High Risk Children From Brazilian Health System Perspective  by Fernandes, R.R.A.
A510  VA L U E  I N  H E A LT H  1 7  ( 2 0 1 4 )  A 3 2 3 – A 6 8 6  
ing an additional unintended pregnancy with ulipristal acetate as compared to 
levonorgestrel is estimated to be 418€ . Ulipristal acetate is most cost-effective in 
the subgroup of intake within 24 hours, where it is more efficacious at a lower cost 
compared to levonorgestrel. ConClusions: Ulipristal acetate is a cost-effective 
alternative to levonorgestrel, given that the cost of avoiding an additional pregnancy 
with ulipristal acetate is less than the average cost of said pregnancies. Therefore, 
French minors should have free access to ulipristal acetate directly in a pharmacy. 
Ulipristal acetate should be used rapidly after unprotected intercourse (within 
24hours) to benefit from its cost-saving potential compared to levonorgestrel use.
PIH35
CervICal assessment WItH Progesterone In tHe PreventIon of 
Preterm BIrtH: a strategy Based on Cost-effeCtIveness
Fonseca E.B.1, Nishikawa A.M.2, Paladini L.2, Clark O.A.C.2
1Universidade Federal da Paraíba, João Pessoa, Brazil, 2Evidencias, Campinas, Brazil
inTRoDuCTion: Preterm birth (PTB) complications are estimated to be the second 
most common cause of death in under-five children and responsible for 3.1million 
neonatal deaths. According to a worldwide analysis, Brazil is one of the top ten 
countries with the highest number of PTB. Considering its long-term costs, strate-
gies that reduce incidence may be cost-effective. Treatment with progesterone is 
one of the interventions recommended for PTB prevention due to the evidence 
supporting its efficacy in women with short cervix and prior history of preterm 
delivery. objeCTives: Determine whether treatment with progesterone for preg-
nant women with a short cervical length < 25mm identified in routine measurement 
of second-trimester transvaginal cervical length by ultrasound in low-risk singleton 
pregnancies is a cost-effective strategy under the Brazilian Healthcare System per-
spective. MeThoDs: A cohort model was developed according to the disease and 
resources use. Epidemiology of pregnancies at risk of PTB eligible for progesterone 
treatment were obtained from published data. To obtain national clinical data, births 
were categorized by gestational week age at delivery specialist opinion. Progesterone 
effectiveness data were obtained from systematic reviews, meta-analysis and spe-
cialist opinion. Costs included screening test, prenatal consultation, progesterone 
and neonatal hospitalization. Exchange rate was 1USD= 2.30BRL. Results were pre-
sented in cost/PTB avoided. ResulTs: Considering 278.100 PTB, the inclusion of 
screening test to identify pregnant women with short cervix and its prophylaxis 
with progesterone shows significant economic savings of USD74 million. Although 
the expenditure on drug, screening test and prenatal consultation increment the 
total costs, the reduced number of PTB (263,052 vs 278.100) and neonatal UTI hos-
pitalization length (4,098,543 days vs 4,518,056 days) resulted in a total economic 
saving. ConClusions: Prevention of PTB is dominant in women with short cervix 
as compared to a no-prophylactic strategy scenario resulting in economic savings 
to the Brazilian health care system.
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objeCTives: This study aimed to investigate the cost-effectiveness of palivizumab 
to different combinations of risk groups, such as premature children born with ges-
tational age (GA) ≤ 28 weeks, GA ≤ 32 weeks, children with congenital heart disease 
and bronchopulmonary dysplasia. MeThoDs: Literature review was performed to 
search effectiveness data. One Markov model (base case), and one decision tree 
(alternative scenario) were built with a cohort simulation along a 18 years-time 
horizon for the base case and a 1 year time horizon for the decision tree. Base case 
consider sequelae after infection, and alternative scenario not. The Health System 
perspective was used, with a discount rate of 5%. A probabilistic sensitivity analysis 
(Monte Carlo simulation) with probability distributions fitted to the variables, was 
performed under the different structural assumptions, as well as a deterministic 
analysis, using Tornado diagram, to verify the variable modifications able to alter 
the responses of the model. A threshold analysis was used to estimate the price 
that palivizumab would fit under an acceptability threshold proposed for the health 
system. ResulTs: The option of using the prophylaxis just in preterm children born 
with GA ≤ 32 weeks dominated all others. The incremental effectiveness of base 
case analysis compared with no prophylaxis (base line) was 0.19 QALY. However, 
this strategy was not cost-effective, presenting an incremental cost-effectiveness 
ratio (ICER) of R$ 81,627.31/QALY, value above of World Health Organization (WHO) 
proposed threshold of three times GDP per capita (R$ 63,756.00/QALY). The ICER of 
GA ≤ 32 weeks in alternative scenario was 2.023.045,72, showing the importance of 
considering sequelae in analysis. Sensitivity analysis showed that some variables 
when altered were able to change model final answers. ConClusions: Threshold 
analyses demonstrated that palivizumab price must be reduced in at least 22% to 
be incorporated to all populations use, based on WHO threshold.
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objeCTives: Children undergoing cardiac surgery for congenital heart disease are 
more likely to experience development of acute kidney injury (AKI) in the immedi-
ate postoperative period. In current clinical practice, AKI diagnosis is based on a 
rise in serum creatinine (sCr) levels, which occurs 2-3 days after the initiating renal 
insult. Many new biomarkers offer promise for earlier AKI diagnosis. The objective 
for RT intervention and US$ 17.88/DALY for RPR intervention. Cost-effectiveness 
ratios (CERs) were more sensitive to the prevalence rate, sensitivity of tests, and 
DALY discount rate. ConClusions: Using the on-site antenatal rapid testing, same 
day treatment for positive results, and confirmed by RPR testing approach is cost-
effective in Mongolia.
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objeCTives: To estimate the cost-effectiveness of the supply of calcium of 1200mg 
per day from the week 14 of pregnancy to all pregnant women compared to not 
supplying it to reduce the incidence of preeclampsia. MeThoDs: A decision tree 
was built in TreeAge® with outcome measured in life years gained (LYG) associated 
to the reduction in maternal deaths. The costs were included from the perspective 
of the Health System in Colombia. Pharmaceutical costs were obtained from 2008 
SISMED (1) and the value of the procedures was calculated by adjusting the values 
of Tariff Manual ISS 2001 + 30% (2), these values were compared with information 
of costs supplied by three EPS. All costs are expressed in Colombian pesos of 2010. 
The discount rate was 0%. It was performed sensitivity univariate and probabilistic 
analyzes for costs and effectiveness. ResulTs: Compared to no intervention, calcium 
supplement is a dominant alternative. If the incidence of preeclampsia is lower than 
51.7 per 1000 pregnant women or the cost per tablet of calcium of 600 mg is greater 
than $454, calcium supplement is no longer a cost-effective alternative in Colombia 
for a threshold of 3 times the GDP per capita in Colombia of 2010 by LYG, equal to 
$36,143,550. ConClusions: Supply of calcium to all pregnant women from week 
14 of gestation is a dominant alternative compared to no intervention, which saves 
200 LYG, while it decreases costs in the order of $5,304 million pesos per 100.000 
pregnant women.
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objeCTives: Ulipristal acetate is a selective progesterone receptor modulator 
that has been demonstrated to be an effective 3-month pre-operative treatment 
for moderate to severe symptoms of uterine fibroids in adult women of repro-
ductive age. The aim of this analysis was to assess the cost-effectiveness of 5 mg 
ulipristal acetate as an add-on therapy to standard pre-surgical observation and 
treatment or immediate hysterectomy in Romania. MeThoDs: A Markov model 
was developed using a 10-year time horizon. Ulipristal acetate was compared with 
pre-surgical observation and immediate hysterectomy. The model comprised the 
following mutually exclusive health states: mild, moderate, severe, or persistent 
severe excessive bleeding disorder; myomectomy; post-myomectomy with mildly to 
moderately excessive bleeding disorder; post-myomectomy with severely excessive 
bleeding disorder; hysterectomy; post-hysterectomy; post-menopause; and death. 
Transition probabilities and utility values were obtained from clinical trials and the 
scientific literature. Resource utilisation and unit costs were derived from the con-
sensus panel of clinical experts and the Romanian National Insurance House tariffs. 
Cost vectors in RON were converted to EUR by using 2013 Romanian National Bank 
average exchange rate (1 EUR = 4.419 RON). ResulTs: Adding a 3-month course of 
ulipristal acetate to pre-operative observation was predicted to achieve an addi-
tional 0.021 quality-adjusted life years (QALYs) at an estimated incremental cost of 
367 € , which would result in an incremental cost of 17,749 € /QALY. When 3 months 
of ulipristal acetate therapy was compared with immediate hysterectomy, the incre-
mental cost-effectiveness ratio was reduced to 2,300 € /QALY. The results were most 
sensitive to the utility value of the post-hysterectomy health state but responsive 
to changes in other model parameters. ConClusions: The results of this analysis 
suggest that adding ulipristal acetate treatment to standard pre-surgical therapy 
represents a good value for money in Romania. The inclusion of societal benefits 
may considerably reduce the cost-effectiveness ratio.
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objeCTives: To compare the cost and effectiveness of two emergency contracep-
tive methods in minors in France and to support the payer’s analysis if it is worth 
to deliver ulipristal acetate for free to minors. MeThoDs: Based on a decision-
analytical model, the cost-effectiveness of two emergency contraceptive meth-
ods is compared. Pregnancy rates, outcome of unintended pregnancy in minors 
and resource utilization are derived from literature. Resources and their costs are 
considered until termination or a few days after delivery. Costs are taken from a col-
lective perspective. Sensitivity analyses are performed on the most sensitive input 
parameters. ResulTs: Using emergency contraception is superior to no method. 
The cost of an unintended pregnancy in a French minor is estimated to be 1630€ 
(1330€ - 1803€ ). Almost 4 million€ (3.1-13.7million€ ) could have been saved by using 
ulipristal acetate instead of levonorgestrel in 2010. The incremental cost of avoid-
